This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Barbara L. Beasley, MD; Roger W. Davenport, MD; Thomas N. Chase, MD

Arch Neurol. 1977;34(4):255-256.

Abstract
• The oral administration of fenfluramine hydrochloride, which acts centrally to augment serotonin-mediated synaptic function, did not alter extrapyramidal signs in either untreated or levodopatreated parkinsonian patients. These results support the contention that biochemical indices of serotonergic dysfunction in Parkinson disease do not reflect a critical role for serotonin-containing neural systems in the pathophysiology of parkinsonism and that serotonin-active drugs afford no significant therapeutic benefit to patients with this disorder.

Author Affiliations
From the Departments of Neurology, US Public Health Service Hospital, Staten Island, NY (Dr Beasley), and the Downstate Medical Center, Brooklyn, NY (Dr Davenport), and the Experimental Therapeutics Branch (Dr Chase), National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, Md.

Footnotes
Accepted for publication Dec 28, 1976.

Reprint requests to National Institute of Neurological and Communicative Disorders and Stroke, 9000 Rockville Pike, Bethesda, MD 20014 (Dr Chase).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treatment With Tryptophan of Levodopa-Associated Psychiatric Disturbances
Beasley et al.
Arch Neurol 1980;37:155-156.
ABSTRACT